Evaluation of the anti-bacterial agents compsumption in the Intensive Care Unit from 2016 to 2020 in a second-level hospital
DOI:
https://doi.org/10.60103/phc.v24i5.784Keywords:
Antimicrobials; Antimicrobial Stewardship Program; Critical Care; Health Indicators; Intensive Care UnitsAbstract
Objective: Monitoring the consumption of antimicrobials in hospitals is a necessary measure to evaluate the rational use of these drugs. The main indicator to carry out this monitoring and to know the pressure or exposure of antimicrobials at the hospital level is the defined daily dose (DDD) for every 100 stays and day (s-d). The main objective is to analyze the evolution of the use of antibiotics in an Intensive Care Unit (ICU) of a second level hospital over 5 years.
Methods: It was carried out an observational, retrospective study that analyzes the consumption of antibiotics in the ICU, making a comparison with the global data of the hospital, using DDD/100 s-d as the unit of measurement.
Results: 28 drugs were included, corresponding to 25 active ingredients. The mean global hospital consumption was 67.98; rising to 89.17 in the ICU. There was a trend towards reductions in consumption until 2020, when antibiotics such as azithromycin or ceftriaxone stand out. In the ICU, the most consumed drugs in 2016 were meropenem and amoxicillin/clavulanate, followed by ciprofloxacin and piperacillin/tazobactam. However, in 2020, meropenem and amoxicillin/clavulanate, in spite of showing lower values, continued to be the most used ones, while ciprofloxacin became one of the least used.
Conclusions: The analysis of DDD/100 s-d in the ICU is a useful tool to monitor the consumption of antimicrobials and see consumption trends, which will allow the implementation of measures that promote the rational and safe use of these drugs.
Downloads
References
Antibiotic resistance [Internet]. [cited February 9, 2022]. Available at: https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance
Hermosilla Nájera L, Canut Blasco A, Ulibarrena Sanz M, Abásolo Osinaga E, Abecia Inchaurregui L.C. Evolución de la utilización de antimicrobianos durante los años 1996-2000 en un hospital general. Estudio pormenorizado de la UCI. Farm Hosp. 2003, 27(1):31-37. Available at: https://www.elsevier.es/es-revista-farmacia-hospitalaria-121-articulo-evolucion-utilizacion-antimicrobianos-durante-anos-13118736
Collado R, Losa JE, Álvaro EAq, Toro P, Moreno L, Pérez M. Evaluación del consumo de antimicrobianos mediante DDD/100 estancias versus DDD/100 altas en la implantación de un Programa de Optimización del Uso de Antimicrobianos. Revista Española de Quimioterapia. [Internet]. 2015; 28: 317-321. Available at: https://www.semanticscholar.org/paper/Evaluaci%C3%B3n-del-consumo-de-antimicrobianos-mediante-Collado-Losa/52fcf75f7d5ac9fe2114487268af7ae1725dfbaf
Rodríguez-Baño J, Paño-Pardo JR, Alvarez-Rocha L, Asensio A, Calbo E, Cercenado E, et al. Programs for optimizing the use of antibiotics (PROA) in Spanish hospitals: GEIH-SEIMC, SEFH and SEMPSPH consensus document. Enferm Infecc Microbiol Clin. January 2012;30(1):22.e1-22.e23. http://dx.doi.org/10.1016/j.eimc.2011.09.018
Kuster SP, Ruef C, Ledergerber B, Hintermann A, Deplazes C, Neuber L, et al. Quantitative antibiotic use in hospitals: comparison of measurements, literature review, and recommendations for a standard of reporting. Infection. December 2008;36(6):549–59. http://dx.doi.org/10.1007/s15010-008-7462-z
Aparaci Bolufer JV, Taboada Montero C. Estudio de la utilización de antibióticos de un hospital comarcal. Años 1998-2002. Farmacia Hospitalaria. 2004;28(6):410–8. Available at: https://www.elsevier.es/es-revista-farmacia-hospitalaria-121-pdf-13118709
WHOCC - ATC/DDD Index [Internet]. [cited January 26, 2022]. Available at: https://www.whocc.no/atc_ddd_index/
MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev. October 2005;18(4):638–56. http://dx.doi.org/10.1128/CMR.18.4.638-656.2005
Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. December 2, 2009;302(21):2323–9. http://dx.doi.org/10.1001/jama.2009.1754
Informe ENVIN-UCI 2020.pdf [Internet]. [cited March 14, 2022]. Available at: https://hws.vhebron.net/envin-helics/Help/Informe%20ENVIN-UCI%202020.pdf
Khan S, Hasan SS, Bond SE, Conway BR, Aldeyab MA. Antimicrobial consumption in patients with COVID-19: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2022;20(5):749-772. http://dx.doi.org/10.1080/14787210.2022.2011719
Olry de Labry-Lima A, Saez-de la Fuente J, Abdel-Kader Martin L, Alegre-del Rey EJ, García-Cabrera E, Sierra-Sánchez JF. Factores asociados a la mortalidad en pacientes hospitalizados por COVID-19 en España. Datos del Registro Español de Resultados de Farmacoterapia frente a COVID-19 (RERFAR). Farm Hosp. 2022;46(2):57-71. http://dx.doi.org/10.7399/fh.11714
Ul Mustafa Z, Salman M, Aldeyab M, Kow CS, Hasan SS. Antimicrobial consumption among hospitalized patients with COVID-19 in Pakistan. SN Compr Clin Med. 2021;3(8):1691–1695. http://dx.doi.org/10.1007/s42399-021-00966-5
Cantudo-Cuenca MR, Jimenez-Morales A, Martínez-de la Plata JE. Pharmacist-driven antimicrobial stewardship program in a long-term care facility by assessment of appropriateness. Sci Rep. 2021;11(1):18884. http://dx.doi.org/10.1038/s41598-021-98431-9 . Retraction in: Sci Rep. 2021;11(1):20580. http://dx.doi.org/10.1038/s41598-021-00221-w
Nakamura S, Arima T, Tashiro R, Yasumizu S, Aikou H, Watanabe E, et al. Impact of an antimicrobial stewardship in a 126-bed community hospital with close communication between pharmacists working on post-prescription audit, ward pharmacists, and the antimicrobial stewardship team. J Pharm Health Care Sci. 2021;7(1):25. http://dx.doi.org/doi:10.1186/s40780-021-00206-x
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Tania González Furelos, Iria Rodríguez Legazpi, Eva Fraga Bueno, Isaura Rodríguez Penín
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
La revista Pharmaceutical Care España se publica bajo una licencia «Creative Commons, Reconocimiento, No Comercial y Compartir Igual 4.0 Internacional» (CC BY-NC-SA 4.0)», que permite a otros compartir el trabajo con un reconocimiento de la autoría del trabajo y la publicación inicial en esta revista (con excepción de los usos comerciales).
Los autores que publican en esta revista están de acuerdo con los siguientes términos:a) Los autores conservan los derechos de autor (derechos morales) y garantizan a la revista el derecho de ser el primer soporte documental publicado del trabajo.
b) Se permite y anima a los autores a difundir la versión del trabajo revisado por pares y aceptada para su publicación (por ejemplo, en repositorios institucionales o temáticos), recomendando hacerlo con la versión final del editor “pdf”, “html” o “xml”).